[ { "company": "CG Oncology", "ticker": "CGON", "market": "Nasdaq", "drug": "Cretostimogene grenadenorepvec", "indication": "Intermediate-risk non-muscle invasive bladder cancer", "mechanism": "PIVOT-006 trial", "catalyst_date": "2026-01-01", "date_precision": "year", "date_display": "2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "needs_check", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing says topline is \"anticipated in the near-term\" and gives no dated window — the year here is a placeholder, not company guidance. Confirm before trusting the timing." }, { "company": "Sagimet Biosciences", "ticker": "SGMT", "market": "Nasdaq", "drug": "TVB-3567", "indication": "Acne (FASN inhibitor)", "mechanism": "First-in-human Phase 1 trial", "catalyst_date": "2026-01-01", "date_precision": "year", "date_display": "2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435dex992.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Phase 1 clinical trial results anticipated in 2026.\" Year-level guidance only." }, { "company": "Kyverna Therapeutics", "ticker": "KYTX", "market": "Nasdaq", "drug": "Miv-cel (mivotacel)", "indication": "Stiff person syndrome", "mechanism": "KYSA-8 trial", "catalyst_date": "2026-07-01", "date_precision": "quarter", "date_display": "Q3 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/kytx-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "CAR-T for autoimmune disease. Filing states the company \"plans to report 12-month topline data from KYSA-8 in Q3 2026.\"" }, { "company": "Apogee Therapeutics", "ticker": "APGE", "market": "Nasdaq", "drug": "APG279 (zumilokibart + APG990)", "indication": "Atopic dermatitis", "mechanism": "APG279 head-to-head trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/apge-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states \"interim data expected in 2H 2026\" for the head-to-head study against dupilumab." }, { "company": "Monte Rosa Therapeutics", "ticker": "GLUE", "market": "Nasdaq", "drug": "MRT-8102", "indication": "Elevated cardiovascular disease risk (NEK7 degrader)", "mechanism": "GFORCE-1 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Readout of MRT-8102 GFORCE-1 study in subjects with elevated CVD risk anticipated in H2 2026.\"" }, { "company": "Arcus Biosciences", "ticker": "RCUS", "market": "Nasdaq", "drug": "Casdatifan + zimberelimab", "indication": "First-line clear cell renal cell carcinoma", "mechanism": "ARC-20 first-line cohorts trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "HIF-2a inhibitor. Filing guides \"initial data from the ARC-20 cohorts evaluating casdatifan in early-line settings\" in the second half of 2026." }, { "company": "Arcus Biosciences", "ticker": "RCUS", "market": "Nasdaq", "drug": "Casdatifan + cabozantinib", "indication": "Second-line clear cell renal cell carcinoma", "mechanism": "ARC-20 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "Filing guides \"more mature overall response rate data and initial PFS data ... for approximately 45 patients\" in the second half of 2026." }, { "company": "Arcturus Therapeutics", "ticker": "ARCT", "market": "Nasdaq", "drug": "ARCT-810", "indication": "Ornithine transcarbamylase deficiency", "mechanism": "Phase 2 trial", "catalyst_date": "2026-07-01", "date_precision": "quarter", "date_display": "Q3 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Data and the regulatory plan for this program is expected to be communicated later this quarter.\"" }, { "company": "Invivyd", "ticker": "IVVD", "market": "Nasdaq", "drug": "VYD2311", "indication": "COVID-19 prevention (monoclonal antibody)", "mechanism": "DECLARATION trial", "catalyst_date": "2026-07-01", "date_precision": "quarter", "date_display": "Q3 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"top-line data planned later in Q3 2026\" from the pivotal trial supporting a BLA." }, { "company": "Invivyd", "ticker": "IVVD", "market": "Nasdaq", "drug": "VYD2311", "indication": "COVID-19 safety versus mRNA vaccine", "mechanism": "LIBERTY trial", "catalyst_date": "2026-07-01", "date_precision": "quarter", "date_display": "Q3 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"top-line data anticipated in late Q3 2026\" from the fully dosed safety study." }, { "company": "Acrivon Therapeutics", "ticker": "ACRV", "market": "Nasdaq", "drug": "ACR-368", "indication": "Serous endometrial cancer", "mechanism": "Phase 2b serous EC arms trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2B readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"a prespecified simultaneous interim analysis and data update from both all-comer ... serous EC arms of the ACR-368 Phase 2b study in second half of 2026.\"" }, { "company": "Tvardi Therapeutics", "ticker": "TVRD", "market": "Nasdaq", "drug": "TTI-101", "indication": "Hepatocellular carcinoma (STAT3 inhibitor)", "mechanism": "REVERT HCC trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1B/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1346830/000110465926088461/tm2621651d1_ex99-2.htm", "source_date": "2026-07-30", "verified_on": "2026-09-12", "outcome": null, "note": "Company presentation guides \"Phase 1b/2 topline data 2H:2026.\"" }, { "company": "enGene Holdings", "ticker": "ENGN", "market": "Nasdaq", "drug": "Detalimogene voraplasmid", "indication": "Non-muscle invasive bladder cancer", "mechanism": "LEGEND trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/engn-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Enrollment Complete: 12-Month Data Update Expected 2H 2026\" from the pivotal cohort." }, { "company": "enGene Holdings", "ticker": "ENGN", "market": "Nasdaq", "drug": "Detalimogene voraplasmid", "indication": "Non-muscle invasive bladder cancer", "mechanism": "BLA submission trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/engn-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Pivotal Cohort 12-month Data and Filing of BLA Expected in 2H 2026.\"" }, { "company": "Ocugen", "ticker": "OCGN", "market": "Nasdaq", "drug": "OCU410ST", "indication": "Stargardt disease (modifier gene therapy)", "mechanism": "GARDian3 trial", "catalyst_date": "2026-07-01", "date_precision": "quarter", "date_display": "Q3 2026", "catalyst_type": "Phase 2/3 readout", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1372299/000110465926105968/tm2624985d1_ex99-1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-14", "outcome": "Interim analysis completed, reported 8 September 2026 — the independent DMC reviewed the pre-specified interim analysis of atrophic lesion size in the GARDian3 trial and recommended the study continue per protocol, with follow-up extended to 8 months for the full population. Topline data now guided for mid-2027.", "note": "Filing states: \"After completing a pre-specified interim analysis of atrophic lesion size in the Phase 2/3 clinical trial of OCU410ST in Stargardt disease, the independent Data Monitoring Committee (DMC) recommended continuing the study according to the protocol except with a modification to obtain 8 months of follow-up on lesion size in the entire study population.\" Correcting a data error: the trial is GARDian3, not ArMaDa (ArMaDa is Ocugen’s separate OCU410/dry-AMD program)." }, { "company": "Roivant Sciences", "ticker": "ROIV", "market": "Nasdaq", "drug": "Brepocitinib", "indication": "Non-infectious uveitis", "mechanism": "Phase 3 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026.\"" }, { "company": "Roivant Sciences", "ticker": "ROIV", "market": "Nasdaq", "drug": "IMVT-1402", "indication": "Cutaneous lupus erythematosus", "mechanism": "Proof-of-concept trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) topline data expected in the second half of calendar year 2026.\" Programme runs through Immunovant (IMVT), Roivant's listed subsidiary." }, { "company": "Roivant Sciences", "ticker": "ROIV", "market": "Nasdaq", "drug": "Mosliciguat", "indication": "Pulmonary hypertension with interstitial lung disease", "mechanism": "Phase 2 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/ef20081686_ex99-1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-14", "outcome": "Positive topline, announced 8 September 2026 — the Phase 2 PHocus study met its primary endpoint: a placebo-adjusted reduction in pulmonary vascular resistance of -56.3% at Week 16 (p<0.0001), plus a +35.2m placebo-adjusted improvement in six-minute walk distance. Advancing to a global Phase 3 (PHrontier).", "note": "Filing reports the Phase 2 PHocus study of mosliciguat in PH-ILD met its primary and key secondary endpoints, and announces initiation of the Phase 3 PHrontier study (~375 patients globally)." }, { "company": "Roivant Sciences", "ticker": "ROIV", "market": "Nasdaq", "drug": "IMVT-1402", "indication": "Difficult-to-treat rheumatoid arthritis", "mechanism": "Registrational programme update trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides an update \"on the potentially registrational program of IMVT-1402 in D2T RA in the second half of calendar year 2026.\"" }, { "company": "Seaport Therapeutics", "ticker": "SPTX", "market": "Nasdaq", "drug": "GlyphAllo", "indication": "Healthy volunteers (neuropsychiatric safety)", "mechanism": "Driving simulation trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": false, "status": "decided", "verification": "reported", "source_type": "Press release", "source_url": "https://www.biospace.com/press-releases/seaport-therapeutics-reports-positive-topline-results-from-phase-1-driving-simulation-trial-of-glyphallo-in-healthy-volunteers", "source_date": "2026-09-09", "verified_on": "2026-09-14", "outcome": "Positive topline, announced 9 September 2026 — evening 375mg dosing did not impair next-morning driving performance vs placebo on Day 5 (primary endpoint met); a key secondary endpoint was also met at 250mg on Day 2. No serious adverse events.", "note": "Company press release reports positive topline results from the Phase 1 driving simulation trial of GlyphAllo in healthy volunteers. No SEC 8-K was found in EDGAR full-text search as of the check date." }, { "company": "CervoMed", "ticker": "CRVO", "market": "Nasdaq", "drug": "Neflamapimod", "indication": "Recovery after stroke", "mechanism": "RESTORE trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2A readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"Topline data from its Phase 2a RESTORE trial evaluating neflamapimod.\"" }, { "company": "Absci", "ticker": "ABSI", "market": "Nasdaq", "drug": "ABS-201", "indication": "Androgenetic (pattern) hair loss", "mechanism": "Proof-of-concept interim trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Absci \"anticipates reporting interim proof-of-concept data from this study in the second half of 2026.\"" }, { "company": "Xencor", "ticker": "XNCR", "market": "Nasdaq", "drug": "Plamotamab", "indication": "Rheumatoid arthritis (CD20 x CD3)", "mechanism": "Phase 1b trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Xencor \"plans to provide an update on progress achieved in the Phase 1b study of plamotamab in RA in 2H26.\"" }, { "company": "Xencor", "ticker": "XNCR", "market": "Nasdaq", "drug": "XmAb657", "indication": "B-cell autoimmune disease (CD19 x CD3)", "mechanism": "Phase 1 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Xencor \"plans to provide an update on progress achieved in the Phase 1 study of XmAb657 in 2H26.\"" }, { "company": "Erasca", "ticker": "ERAS", "market": "Nasdaq", "drug": "ERAS-4001", "indication": "KRAS-mutant solid tumours (pan-KRAS inhibitor)", "mechanism": "BOREALIS-1 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/eras-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Preliminary Phase 1 monotherapy data expected in the second half of 2026.\"" }, { "company": "Caribou Biosciences", "ticker": "CRBU", "market": "Nasdaq", "drug": "CB-011", "indication": "Relapsed/refractory multiple myeloma (allogeneic BCMA CAR-T)", "mechanism": "CaMMouflage trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813xexx991.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"initial safety and efficacy from dose expansion on more than 15 patients with a minimum of three months follow up,\" plus longer follow-up on the 12-patient BCMA-naive dose-escalation cohort." }, { "company": "ArriVent BioPharma", "ticker": "AVBP", "market": "Nasdaq", "drug": "Firmonertinib", "indication": "First-line EGFR exon 20 insertion NSCLC", "mechanism": "FURVENT trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_ex99-1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Top-line data from the global pivotal FURVENT Phase 3 (NCT05607550) study ... is anticipated in 2H 2026.\"" }, { "company": "Eikon Therapeutics", "ticker": "EIKN", "market": "Nasdaq", "drug": "EIK1001", "indication": "Non-squamous NSCLC (TLR7/8 agonist)", "mechanism": "Phase 2 NSCLC trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Company milestone slide guides a \"Full Phase 2 NSCLC data readout\" in 2H 2026." }, { "company": "Eikon Therapeutics", "ticker": "EIKN", "market": "Nasdaq", "drug": "EIK1001", "indication": "Melanoma — first interim analysis", "mechanism": "TeLuRide-006 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Clinical readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Company milestone slide guides a \"First Interim Analysis\" in melanoma in 2H 2026. The filing does not state the phase." }, { "company": "Eikon Therapeutics", "ticker": "EIKN", "market": "Nasdaq", "drug": "EIK1003", "indication": "Advanced solid tumours (PARP1-selective)", "mechanism": "Phase 1/2 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1/2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Company milestone slide guides a \"Full read out of Phase 1/2 study\" plus an \"Initial read out of EIK1003 + abiraterone cohort\" in 2H 2026." }, { "company": "Eikon Therapeutics", "ticker": "EIKN", "market": "Nasdaq", "drug": "EIK1005", "indication": "Advanced solid tumours (WRN helicase inhibitor)", "mechanism": "Phase 1/2 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1/2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Company milestone slide guides \"Initial data from Phase 1/2 study\" in 2H 2026." }, { "company": "Fractyl Health", "ticker": "GUTS", "market": "Nasdaq", "drug": "RJVA-001", "indication": "Type 2 diabetes (pancreatic gene therapy)", "mechanism": "First-in-human trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1572616/000119312526342343/guts-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"First-in-human dosing of RJVA-001, subject to site activation, and expected reporting of preliminary data\" in H2 2026." }, { "company": "Neumora Therapeutics", "ticker": "NMRA", "market": "Nasdaq", "drug": "NMRA-898", "indication": "Schizophrenia (M4 positive allosteric modulator)", "mechanism": "Phase 1 MAD trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/nmra-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Neumora \"expects to report data from the study in the second half of 2026.\"" }, { "company": "C4 Therapeutics", "ticker": "CCCC", "market": "Nasdaq", "drug": "Cemsidomide + elranatamab", "indication": "Multiple myeloma — dose escalation progress", "mechanism": "Phase 1b trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811xexx991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides an \"update on the dose escalation progress from the Phase 1b trial evaluating the combination of cemsidomide.\"" }, { "company": "Insmed", "ticker": "INSM", "market": "Nasdaq", "drug": "Brensocatib (BRINSUPRI)", "indication": "Non-cystic fibrosis bronchiectasis (Japan)", "mechanism": "Japan regulatory decision trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Regulatory milestone", "options": true, "status": "decided", "verification": "reported", "source_type": "Press release", "source_url": "https://www.prnewswire.com/news-releases/brinsupri-brensocatib-approved-by-japans-ministry-of-health-labour-and-welfare-for-the-treatment-of-patients-with-non-cystic-fibrosis-bronchiectasis-a-serious-chronic-lung-disease-302858166.html", "source_date": "2026-08-24", "verified_on": "2026-09-14", "outcome": "Approved in Japan 24 August 2026 — Japan's MHLW approved BRINSUPRI (brensocatib) 25 mg tablet for non-cystic fibrosis bronchiectasis in patients 12 and older, based on the Phase 3 ASPEN data.", "note": "Company press release: Japan's MHLW approved BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis. No separate SEC 8-K was found for this foreign regulatory approval as of the check date." }, { "company": "Arvinas", "ticker": "ARVN", "market": "Nasdaq", "drug": "ARV-806", "indication": "KRAS G12D-mutant solid tumours (degrader)", "mechanism": "Phase 1 monotherapy dose escalation trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides Arvinas will \"share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026.\"" }, { "company": "Arvinas", "ticker": "ARVN", "market": "Nasdaq", "drug": "ARV-393", "indication": "Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader)", "mechanism": "Phase 1 dose escalation trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides sharing \"data from early monotherapy cohorts in the ongoing Phase 1 dose escalation clinical trial.\"" }, { "company": "Palvella Therapeutics", "ticker": "PVLA", "market": "Nasdaq", "drug": "QTORIN rapamycin", "indication": "Microcystic lymphatic malformations", "mechanism": "NDA submission trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Regulatory submission", "options": true, "status": "decided", "verification": "reported", "source_type": "Press release", "source_url": "https://www.globenewswire.com/news-release/2026/08/31/3353213/0/en/palvella-therapeutics-completes-rolling-submission-of-new-drug-application-to-fda-for-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations.html", "source_date": "2026-08-31", "verified_on": "2026-09-14", "outcome": "NDA submission completed 31 August 2026 — Palvella completed its rolling NDA submission to the FDA for QTORIN 3.9% rapamycin gel in microcystic lymphatic malformations.", "note": "Company press release confirms completion of the rolling NDA submission for QTORIN rapamycin gel. No SEC 8-K was found in EDGAR full-text search as of the check date." }, { "company": "Forte Biosciences", "ticker": "FBRX", "market": "Nasdaq", "drug": "FB102", "indication": "Celiac disease (anti-CD122)", "mechanism": "Phase 2 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466dex991.htm", "source_date": "2026-07-27", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Phase 2 data expected in the second half of this year\" (2026)." }, { "company": "Ensysce Biosciences", "ticker": "ENSC", "market": "Nasdaq", "drug": "CY-200", "indication": "Complex regional pain syndrome type 1", "mechanism": "Phase 2 trial", "catalyst_date": "2026-07-01", "date_precision": "half", "date_display": "H2 2026", "catalyst_type": "Phase 2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/ex99-1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing refers to \"the upcoming Phase 2 topline data for CY-200\" in an indication with no approved treatment; guidance is second half of 2026." }, { "company": "Kodiak Sciences", "ticker": "KOD", "market": "Nasdaq", "drug": "Zenkuda (tarcocimab) and KSI-501", "indication": "Wet age-related macular degeneration", "mechanism": "DAYBREAK trial", "catalyst_date": "2026-09-01", "date_precision": "month", "date_display": "Sep 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline data for the one-year primary endpoint (Zenkuda and KSI-501) are expected in September 2026.\" Unusually precise for a readout — still a month, not a day." }, { "company": "Spyre Therapeutics", "ticker": "SYRE", "market": "Nasdaq", "drug": "SPY003", "indication": "Ulcerative colitis", "mechanism": "SKYLINE Part A trial", "catalyst_date": "2026-09-01", "date_precision": "month", "date_display": "Sep 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K", "source_url": "https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/syre-20260908.htm", "source_date": "2026-09-08", "verified_on": "2026-09-14", "outcome": "Positive topline, announced 8 September 2026 — Phase 2 SKYLINE Part A met its primary endpoint with a 10.0-point placebo-adjusted reduction in Robarts Histopathology Index (p<0.0001); clinical remission 20%, endoscopic improvement 30%. Advancing to SKYLINE Part B (combination therapy).", "note": "Filing reports positive Phase 2 SKYLINE Part A topline data for SPY003 in ulcerative colitis; company advancing to SKYLINE Part B combination therapy." }, { "company": "Spyre Therapeutics", "ticker": "SYRE", "market": "Nasdaq", "drug": "SPY072", "indication": "Rheumatoid arthritis", "mechanism": "SKYWAY RA sub-study trial", "catalyst_date": "2026-09-01", "date_precision": "month", "date_display": "Sep 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K", "source_url": "https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/syre-20260825.htm", "source_date": "2026-08-25", "verified_on": "2026-09-14", "outcome": "Reported 25 August 2026 — both doses beat placebo on primary/secondary endpoints in the SKYWAY RA sub-study, but the effect size did not clear Spyre's internal bar to advance SPY072 as RA monotherapy; the company will explore combination approaches or other indications instead.", "note": "Filing reports SKYWAY RA sub-study results for SPY072: statistically significant improvement vs placebo on DAS28-CRP and ACR20, but effect size insufficient to advance as RA monotherapy." }, { "company": "Definium Therapeutics", "ticker": "DFTX", "market": "Nasdaq", "drug": "DT120 ODT", "indication": "Generalised anxiety disorder", "mechanism": "Panorama trial", "catalyst_date": "2026-09-01", "date_precision": "month", "date_display": "Sep 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1813814/000110465926107275/tm2625365d1_ex99-1.htm", "source_date": "2026-09-14", "verified_on": "2026-09-14", "outcome": "Positive topline, announced 14 September 2026 — Panorama, the second Phase 3 study of DT120, met its primary endpoint: a 5.1-point placebo-adjusted reduction in HAM-A score at Week 12 (p<0.0001), with benefit visible from Day 2. Pre-NDA meeting planned for Q4 2026; NDA filing anticipated 1H 2027.", "note": "Filing reports positive topline Phase 3 Panorama results for DT120 ODT in generalized anxiety disorder; pre-NDA meeting planned Q4 2026, NDA filing anticipated 1H 2027." }, { "company": "C4 Therapeutics", "ticker": "CCCC", "market": "Nasdaq", "drug": "Cemsidomide", "indication": "Multiple myeloma — biomarker data at IMS Annual Meeting", "mechanism": "Phase 1 trial", "catalyst_date": "2026-09-01", "date_precision": "month", "date_display": "Sep 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811xexx991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides a poster \"featuring additional biomarker data on cemsidomide’s immunomodulatory effects\" at the IMS Annual Meeting, 23-26 September 2026. Conference-dated catalyst." }, { "company": "Celldex Therapeutics", "ticker": "CLDX", "market": "Nasdaq", "drug": "Barzolvolimab", "indication": "Chronic spontaneous urticaria (anti-KIT)", "mechanism": "EMBARQ-CSU 1 and 2 trial", "catalyst_date": "2026-09-01", "date_precision": "month", "date_display": "Sep 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/exh_991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline data are anticipated in September/October 2026, supporting a planned BLA filing in 2027.\" The filing gives a two-month range, not a single month." }, { "company": "Nuvalent, Inc.", "ticker": "NUVL", "market": "Nasdaq", "drug": "Zidesamtinib", "indication": "ROS1-positive non-small cell lung cancer (TKI pre-treated)", "mechanism": "ROS1-selective inhibitor", "catalyst_date": "2026-09-18", "catalyst_type": "PDUFA date", "options": true, "status": "decided", "verification": "verified", "source_type": "FDA approval notice", "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer", "source_date": "2026-07-22", "verified_on": "2026-09-14", "outcome": "Approved 22 July 2026, almost two months ahead of the PDUFA date — FDA approved zidesamtinib (Jideytro) for adults with ROS1-positive NSCLC previously treated with a ROS1 TKI.", "note": "FDA approval notice: zidesamtinib (Jideytro, Nuvalent) approved for adults with locally advanced or metastatic ROS1-positive NSCLC who received at least one prior ROS1 TKI — well ahead of the September 18, 2026 PDUFA target action date.", "date_precision": "day", "date_display": null }, { "company": "Ultragenyx Pharmaceutical", "ticker": "RARE", "market": "Nasdaq", "drug": "UX111", "indication": "Sanfilippo syndrome type A (MPS IIIA)", "mechanism": "AAV9 gene therapy", "catalyst_date": "2026-09-19", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "reported", "source_type": "Catalyst calendar", "source_url": "https://www.marketbeat.com/fda-calendar/upcoming/", "source_date": "2026-09-10", "verified_on": null, "outcome": null, "note": "One-time gene therapy for a rare, fatal paediatric neurodegenerative disease. Needs confirming against the company's own filing.", "date_precision": "day", "date_display": null }, { "company": "Ionis Pharmaceuticals", "ticker": "IONS", "market": "Nasdaq", "drug": "Zilganersen", "indication": "Alexander disease", "mechanism": "Antisense oligonucleotide", "catalyst_date": "2026-09-22", "catalyst_type": "PDUFA date", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/ef20081649_ex99-1.htm", "source_date": "2026-09-03", "verified_on": "2026-09-14", "outcome": "Approved 3 September 2026, 19 days ahead of the PDUFA date — FDA approved ZANVASTRO (zilganersen) as the first and only disease-modifying treatment for Alexander disease, in pediatric and adult patients.", "note": "FDA approved ZANVASTRO (zilganersen) as the first and only disease-modifying treatment for Alexander disease (AxD), ahead of the September 22, 2026 PDUFA target action date.", "date_precision": "day", "date_display": null }, { "company": "Mirum Pharmaceuticals", "ticker": "MIRM", "market": "Nasdaq", "drug": "Zilurgisertib", "indication": "Fibrodysplasia ossificans progressiva (FOP)", "mechanism": "ALK2 inhibitor", "catalyst_date": "2026-09-26", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Prescription Drug User Fee Act (PDUFA) target action date for the zilurgisertib NDA is September 26, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Structure Therapeutics", "ticker": "GPCR", "market": "Nasdaq", "drug": "Aleniglipron", "indication": "Type 2 diabetes with obesity or overweight", "mechanism": "Phase 2 T2DM trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-11", "outcome": null, "note": "Oral small-molecule GLP-1 agonist. Filing guides results \"in adults living with T2DM and obesity or overweight\" in Q4 2026." }, { "company": "Maze Therapeutics", "ticker": "MAZE", "market": "Nasdaq", "drug": "MZE829", "indication": "APOL1-mediated kidney disease", "mechanism": "HORIZON trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the company \"expects to announce updated data in late 2026 or early 2027\" across three 10-15 patient cohorts. Window spans a year end — treat the timing as soft." }, { "company": "Kyverna Therapeutics", "ticker": "KYTX", "market": "Nasdaq", "drug": "Miv-cel (mivotacel)", "indication": "Progressive multiple sclerosis", "mechanism": "Stanford investigator-initiated trial trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/kytx-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Additional data from the Stanford Phase 1 IIT expected in Q4 2026.\"" }, { "company": "4D Molecular Therapeutics", "ticker": "FDMT", "market": "Nasdaq", "drug": "4D-710", "indication": "Cystic fibrosis lung disease", "mechanism": "AEROW trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-11", "outcome": null, "note": "Inhaled gene therapy. Filing states an \"AEROW Phase 1/2 clinical trial and program update expected in Q4 2026.\"" }, { "company": "Zura Bio", "ticker": "ZURA", "market": "Nasdaq", "drug": "Tibulizumab (ZB-106)", "indication": "Hidradenitis suppurativa", "mechanism": "TibuSHIELD trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811xex991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Dual IL-17A/BAFF inhibitor. Filing states: \"Topline data are anticipated in the fourth quarter of 2026.\"" }, { "company": "SELLAS Life Sciences Group", "ticker": "SLS", "market": "Nasdaq", "drug": "SLS009 (tambiciclib)", "indication": "Newly diagnosed first-line acute myeloid leukaemia", "mechanism": "Phase 2 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-202608118xkexhibit991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing headline: \"28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026.\"" }, { "company": "Enanta Pharmaceuticals", "ticker": "ENTA", "market": "Nasdaq", "drug": "EDP-978", "indication": "Chronic urticaria", "mechanism": "Phase 1 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the company \"expects to report topline data from the trial in the fourth quarter of 2026.\"" }, { "company": "Spyre Therapeutics", "ticker": "SYRE", "market": "Nasdaq", "drug": "SPY072", "indication": "Psoriatic arthritis", "mechanism": "SKYWAY PsA sub-study trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm", "source_date": "2026-08-04", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline proof-of-concept data are expected in the fourth quarter of 2026.\"" }, { "company": "Spyre Therapeutics", "ticker": "SYRE", "market": "Nasdaq", "drug": "SPY072", "indication": "Axial spondyloarthritis", "mechanism": "SKYWAY axSpA sub-study trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm", "source_date": "2026-08-04", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline proof-of-concept data are expected in the fourth quarter of 2026.\"" }, { "company": "Tenaya Therapeutics", "ticker": "TNYA", "market": "Nasdaq", "drug": "TN-201", "indication": "MYBPC3-associated hypertrophic cardiomyopathy", "mechanism": "MyPEAK-1 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1B/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-ex99_1.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "Gene therapy. Filing states Tenaya \"plans to report additional interim data from the MyPEAK-1 clinical trial in the fourth quarter of 2026.\"" }, { "company": "Tenaya Therapeutics", "ticker": "TNYA", "market": "Nasdaq", "drug": "TN-401", "indication": "PKP2-associated arrhythmogenic right ventricular cardiomyopathy", "mechanism": "RIDGE-1 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1B/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-ex99_1.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states Tenaya \"expects to report additional interim data from the RIDGE-1 clinical trial in the fourth quarter of 2026.\"" }, { "company": "Monte Rosa Therapeutics", "ticker": "GLUE", "market": "Nasdaq", "drug": "MRT-2359", "indication": "Advanced castration-resistant prostate cancer", "mechanism": "Phase 1/2 expansion arm trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states Monte Rosa \"plans to provide an update on this patient subset by the end of the year\" — year-end 2026, not a quarter." }, { "company": "Ocular Therapeutix", "ticker": "OCUL", "market": "Nasdaq", "drug": "AXPAXLI (OTX-TKI)", "indication": "Wet age-related macular degeneration", "mechanism": "SOL-R interim safety trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-11", "outcome": null, "note": "Filing describes \"an interim SOL-R safety analysis of patients who have reached Week 52 to be conducted in the fourth quarter of 2026.\" Safety interim, not the efficacy topline." }, { "company": "Verastem Oncology", "ticker": "VSTM", "market": "Nasdaq", "drug": "VS-7375", "indication": "KRAS G12D-mutant solid tumours", "mechanism": "Clinical programme update trial", "catalyst_date": "2026-10-01", "date_precision": "month", "date_display": "Oct 2026", "catalyst_type": "Clinical readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_ex99-1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the company will \"report updated VS-7375 clinical data in October 2026.\" The filing does not name the phase — confirm before labelling it." }, { "company": "Allogene Therapeutics", "ticker": "ALLO", "market": "Nasdaq", "drug": "ALLO-329", "indication": "Autoimmune disease (allogeneic CD19/CD70 CAR-T)", "mechanism": "RESOLUTION trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/allo-20260630xexx991q226.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"remains on track to provide a clinical and translational update in the fourth quarter of 2026.\"" }, { "company": "MacroGenics", "ticker": "MGNX", "market": "Nasdaq", "drug": "MGC026", "indication": "Advanced solid tumours (B7-H3 ADC)", "mechanism": "Phase 1 dose expansion trial", "catalyst_date": "2026-10-01", "date_precision": "month", "date_display": "Oct 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/exhibit99-1earningspressre.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states interim Phase 1 results were \"accepted for poster presentation at the European Society for Medical Oncology (ESMO) 2026 Congress in October.\"" }, { "company": "MacroGenics", "ticker": "MGNX", "market": "Nasdaq", "drug": "MGC028", "indication": "Advanced solid tumours (ADAM9 ADC)", "mechanism": "Phase 1 dose escalation trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/exhibit99-1earningspressre.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"anticipates providing an update with preliminary clinical results in late 2026.\"" }, { "company": "Arcturus Therapeutics", "ticker": "ARCT", "market": "Nasdaq", "drug": "ARCT-032", "indication": "Cystic fibrosis (inhaled mRNA)", "mechanism": "Phase 2 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"The decision to advance ARCT-032 into Phase 3 is expected in Q4 2026\" — the decision follows the Phase 2 data." }, { "company": "Aptevo Therapeutics", "ticker": "APVO", "market": "Nasdaq", "drug": "Mipletamig + venetoclax/azacitidine", "indication": "Frontline acute myeloid leukaemia", "mechanism": "RAINIER trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 1B/2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/apvo-ex99_1.htm", "source_date": "2026-09-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the Phase 1b portion \"is expected to be completed by year-end\" 2026." }, { "company": "PMV Pharmaceuticals", "ticker": "PMVP", "market": "Nasdaq", "drug": "Rezatapopt", "indication": "TP53 Y220C-mutant solid tumours", "mechanism": "PYNNACLE trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/d441751dex991.htm", "source_date": "2026-08-31", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states PMV \"plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts at a medical conference in fourth quarter of 2026.\"" }, { "company": "Corvus Pharmaceuticals", "ticker": "CRVS", "market": "Nasdaq", "drug": "Soquelitinib", "indication": "Atopic dermatitis (ITK inhibitor)", "mechanism": "Phase 1b/2 cohort 1 trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/exh_991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Results from cohort 1 ... are anticipated late this year.\"" }, { "company": "Candel Therapeutics", "ticker": "CADL", "market": "Nasdaq", "drug": "Linoserpaturev (CAN-2409)", "indication": "Recurrent high-grade glioma", "mechanism": "Phase 1b arm C trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"expects to present potential long-term survival data from arm C of its phase 1b clinical trial ... in Q4 2026.\"" }, { "company": "Candel Therapeutics", "ticker": "CADL", "market": "Nasdaq", "drug": "Aglatimagene besadenovec (CAN-2409)", "indication": "Localised prostate cancer", "mechanism": "BLA submission trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Submission of a BLA for aglatimagene in prostate cancer is planned for Q4 2026.\"" }, { "company": "Jasper Therapeutics", "ticker": "JSPR", "market": "Nasdaq", "drug": "KP-104", "indication": "Rare renal indications (complement inhibitor)", "mechanism": "Phase 2 basket trial trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/ea030204901ex99-1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"interim data from Stage 1 of the trial is expected in the fourth quarter of 2026.\"" }, { "company": "CG Oncology", "ticker": "CGON", "market": "Nasdaq", "drug": "Cretostimogene grenadenorepvec", "indication": "High-risk BCG-unresponsive NMIBC", "mechanism": "BLA submission trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026.\"" }, { "company": "Alumis", "ticker": "ALMS", "market": "Nasdaq", "drug": "Envudeucitinib", "indication": "Plaque psoriasis (TYK2 inhibitor)", "mechanism": "ONWARD3 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-2.htm", "source_date": "2026-09-01", "verified_on": "2026-09-12", "outcome": null, "note": "Company milestone slide guides \"Q426: Topline Data\" for ONWARD3." }, { "company": "Annexon", "ticker": "ANNX", "market": "Nasdaq", "drug": "Tanruprubart", "indication": "Guillain-Barré syndrome", "mechanism": "BLA submission trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1528115/000119312526345672/d119960dex991.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.\"" }, { "company": "Annexon", "ticker": "ANNX", "market": "Nasdaq", "drug": "Vonaprument", "indication": "Geographic atrophy (Month 15 primary endpoint)", "mechanism": "ARCHER II trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1528115/000119312526345672/d119960dex991.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the \"Month 15 primary endpoint on track for the fourth quarter of 2026.\"" }, { "company": "Annexon", "ticker": "ANNX", "market": "Nasdaq", "drug": "ANX1502", "indication": "Cold agglutinin disease", "mechanism": "Proof-of-concept trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1528115/000119312526345672/d119960dex991.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states an \"Update on POC trial in CAD anticipated in the Fall of 2026.\"" }, { "company": "Lexeo Therapeutics", "ticker": "LXEO", "market": "Nasdaq", "drug": "LX2020", "indication": "PKP2 arrhythmogenic cardiomyopathy (gene therapy)", "mechanism": "Phase 1/2 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides a \"12-month data update for all high dose participants in Q4 2026.\"" }, { "company": "IN8bio", "ticker": "INAB", "market": "Nasdaq", "drug": "INB-100", "indication": "Leukaemia (gamma-delta T cell therapy)", "mechanism": "Phase 1 trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/inab-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides an \"INB-100 program clinical update at a scientific meeting in late 2026.\"" }, { "company": "CervoMed", "ticker": "CRVO", "market": "Nasdaq", "drug": "Neflamapimod", "indication": "Non-fluent variant primary progressive aphasia (biomarker data)", "mechanism": "Phase 2a nfvPPA trial", "catalyst_date": "2026-10-01", "date_precision": "month", "date_display": "Oct 2026", "catalyst_type": "Phase 2A readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"12-week biomarker data from the first eight participants\" at the ISFTD conference, 8-11 October 2026." }, { "company": "Faeth Therapeutics", "ticker": "FTH", "market": "Nasdaq", "drug": "PIK-201 (PIKTOR)", "indication": "Endometrial cancer", "mechanism": "Phase 2 trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/d168633dex991.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"topline data from our Phase 2 PIK-201 trial in endometrial cancer, which is expected by year-end\" 2026." }, { "company": "Xencor", "ticker": "XNCR", "market": "Nasdaq", "drug": "XmAb819", "indication": "Advanced clear cell renal cell carcinoma (ENPP3 x CD3)", "mechanism": "Phase 1 trial", "catalyst_date": "2026-10-01", "date_precision": "month", "date_display": "Oct 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Phase 1 results for patients with advanced ccRCC were accepted for a proffered paper oral presentation at the ESMO Congress 2026\" (Madrid, 23-27 October). Conference-dated rather than quarter-guided." }, { "company": "Xencor", "ticker": "XNCR", "market": "Nasdaq", "drug": "XmAb942", "indication": "Ulcerative colitis (anti-TL1A) — blinded interim analysis", "mechanism": "XENITH-UC trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states enrolment \"continue[s] to support a XENITH-UC blinded interim analysis around year-end 2026.\"" }, { "company": "CytomX Therapeutics", "ticker": "CTMX", "market": "Nasdaq", "drug": "Varseta-M (CX-2051)", "indication": "Metastatic colorectal cancer (EpCAM ADC)", "mechanism": "Phase 1 monotherapy trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"A Phase 1 data update is expected by the end of 2026 with a focus on dose selection for late phase development.\"" }, { "company": "MBX Biosciences", "ticker": "MBX", "market": "Nasdaq", "drug": "MBX 4291", "indication": "Obesity (long-acting GLP-1/GIP peptide prodrug)", "mechanism": "Phase 1 MAD Part C trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/mbx-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"Results from the first cohort of the 12-week MAD (Part C) portion of the ongoing Phase 1 trial\" in Q4 2026." }, { "company": "Compass Therapeutics", "ticker": "CMPX", "market": "Nasdaq", "drug": "Tovecimig", "indication": "Biliary tract cancer (DLL4 x VEGF-A bispecific)", "mechanism": "COMPANION-002 trial", "catalyst_date": "2026-10-01", "date_precision": "month", "date_display": "Oct 2026", "catalyst_type": "Phase 2/3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states data \"has also been selected for an oral presentation at the 2026 ESMO Congress in October.\" Conference-dated catalyst." }, { "company": "Compass Therapeutics", "ticker": "CMPX", "market": "Nasdaq", "drug": "CTX-8371", "indication": "TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1)", "mechanism": "Phase 1 cohort expansions trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Additional data from the cohort expansions are expected in Q4 2026.\"" }, { "company": "Compass Therapeutics", "ticker": "CMPX", "market": "Nasdaq", "drug": "CTX-10726", "indication": "Solid tumours (PD-1 x VEGF-A bispecific)", "mechanism": "Phase 1 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"The study is actively enrolling, with initial clinical data expected in Q4 2026.\"" }, { "company": "Aprea Therapeutics", "ticker": "APRE", "market": "Nasdaq", "drug": "APR-1051", "indication": "Advanced solid tumours (WEE1 inhibitor)", "mechanism": "ACESOT-1051 trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/apre-20260812xex99d1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Aprea \"expects to report the next clinical data update from ACESOT-1051 at a medical meeting in the fourth quarter of 2026.\"" }, { "company": "Fractyl Health", "ticker": "GUTS", "market": "Nasdaq", "drug": "Revita", "indication": "Post-GLP-1 weight maintenance — 6-month randomised data", "mechanism": "REMAIN-1 pivotal trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Clinical readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1572616/000119312526342343/guts-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"Topline 6-month randomized data from the REMAIN-1 Pivotal Cohort\" in early Q4 2026." }, { "company": "SpyGlass Pharma", "ticker": "SGP", "market": "Nasdaq", "drug": "BIM-DRS", "indication": "Open-angle glaucoma and ocular hypertension", "mechanism": "Phase 1/2 follow-up trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1/2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/exhibit991-8kprx080626.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Four-year efficacy and safety follow-up expected in fourth quarter of 2026.\"" }, { "company": "Neumora Therapeutics", "ticker": "NMRA", "market": "Nasdaq", "drug": "NMRA-511", "indication": "Alzheimer’s disease agitation (V1a antagonist)", "mechanism": "MAD expansion cohort trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/nmra-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides data \"from a MAD expansion cohort ... in the fourth quarter of 2026.\"" }, { "company": "Attovia Therapeutics", "ticker": "ATTO", "market": "Nasdaq", "drug": "ATTO-1310", "indication": "Chronic pruritus and high-itch atopic dermatitis (IL-31)", "mechanism": "Phase 1b trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 1B readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/atto-ex99_1.htm", "source_date": "2026-09-02", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Complete Phase 1b data are expected in the fourth quarter of 2026.\"" }, { "company": "Rapport Therapeutics", "ticker": "RAPP", "market": "Nasdaq", "drug": "RAP-219", "indication": "Bipolar mania (AMPA receptor modulator)", "mechanism": "Phase 2 trial", "catalyst_date": "2026-10-01", "date_precision": "month", "date_display": "Oct 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"The Phase 2 trial continues to progress, with topline results expected in October 2026.\"" }, { "company": "Rapport Therapeutics", "ticker": "RAPP", "market": "Nasdaq", "drug": "RAP-219", "indication": "Focal onset seizures — open-label safety", "mechanism": "Open-label long-term safety trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Clinical readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"initial data expected in the fourth quarter of 2026\" from the open-label long-term safety trial." }, { "company": "Arvinas", "ticker": "ARVN", "market": "Nasdaq", "drug": "ARV-102", "indication": "Parkinson’s disease (LRRK2 degrader) — biomarker data", "mechanism": "Phase 1 trial", "catalyst_date": "2026-10-01", "date_precision": "month", "date_display": "Oct 2026", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"additional biomarker data from the Phase 1 clinical trial ... at the International Congress on Parkinson’s Disease.\" Conference-dated catalyst." }, { "company": "Celldex Therapeutics", "ticker": "CLDX", "market": "Nasdaq", "drug": "Barzolvolimab", "indication": "Atopic dermatitis", "mechanism": "Phase 2 trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/exh_991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline data from this study are expected to be presented in late 2026.\"" }, { "company": "Kymera Therapeutics", "ticker": "KYMR", "market": "Nasdaq", "drug": "KT-621", "indication": "Atopic dermatitis (oral STAT6 degrader)", "mechanism": "BROADEN2 trial", "catalyst_date": "2026-10-01", "date_precision": "half", "date_display": "Late 2026", "catalyst_type": "Phase 2B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm", "source_date": "2026-06-25", "verified_on": "2026-09-12", "outcome": null, "note": "Filing moves the \"anticipated topline data readout to year-end 2026,\" six months earlier than the prior mid-2027 guidance. A pulled-forward readout is itself a signal." }, { "company": "EyePoint", "ticker": "EYPT", "market": "Nasdaq", "drug": "DURAVYU (vorolanib insert)", "indication": "Wet age-related macular degeneration", "mechanism": "LUCIA trial", "catalyst_date": "2026-10-01", "date_precision": "quarter", "date_display": "Q4 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm", "source_date": "2026-09-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides the company will \"Report topline data from the Phase 3 LUCIA wet AMD trial\" in Q4 2026, with a pre-NDA meeting the same quarter." }, { "company": "60 Degrees Pharmaceuticals", "ticker": "SXTP", "market": "Nasdaq", "drug": "Tafenoquine", "indication": "Babesiosis (interim analysis)", "mechanism": "Multiple treatment studies trial", "catalyst_date": "2026-10-06", "date_precision": "day", "date_display": "06 Oct 2026", "catalyst_type": "Clinical readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1946563/000121390026098056/ea030486201ex99-1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-12", "outcome": null, "note": "Company deck gives an exact interim-analysis date of 10/6/2026. The same deck references a potential sNDA filing and PDUFA date but gives no timing for either." }, { "company": "Merck & Co.", "ticker": "MRK", "market": "NYSE", "drug": "Ifinatamab deruxtecan (I-DXd)", "indication": "Small cell lung cancer", "mechanism": "B7-H3-directed antibody-drug conjugate", "catalyst_date": "2026-10-10", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "reported", "source_type": "Catalyst calendar", "source_url": "https://www.marketbeat.com/fda-calendar/upcoming/", "source_date": "2026-09-10", "verified_on": null, "outcome": null, "note": "Partnered with Daiichi Sankyo. Needs confirming against the company's own filing.", "date_precision": "day", "date_display": null }, { "company": "Ionis Pharmaceuticals", "ticker": "IONS", "market": "Nasdaq", "drug": "Bepirovirsen", "indication": "Chronic hepatitis B", "mechanism": "Antisense oligonucleotide, partnered with GSK", "catalyst_date": "2026-10-26", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_ex99-1.htm", "source_date": "2026-07-29", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Granted Priority Review in the U.S. and PDUFA target action date of October 26, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Inovio Pharmaceuticals", "ticker": "INO", "market": "Nasdaq", "drug": "INO-3107", "indication": "Recurrent respiratory papillomatosis (RRP)", "mechanism": "DNA immunotherapy, accelerated approval pathway", "catalyst_date": "2026-10-30", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm", "source_date": "2026-08-12", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the BLA \"continues to advance under the Agency's accelerated approval program toward a PDUFA target action date of October 30, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Cytokinetics", "ticker": "CYTK", "market": "Nasdaq", "drug": "Aficamten", "indication": "Hypertrophic cardiomyopathy (MAPLE-HCM sNDA)", "mechanism": "Cardiac myosin inhibitor", "catalyst_date": "2026-11-14", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm", "source_date": "2026-05-05", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"The Supplemental New Drug Application for MAPLE-HCM was accepted for filing by the FDA with a PDUFA date of November 14, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Savara Inc.", "ticker": "SVRA", "market": "Nasdaq", "drug": "Molgramostim", "indication": "Autoimmune pulmonary alveolar proteinosis (aPAP)", "mechanism": "Inhaled GM-CSF", "catalyst_date": "2026-11-22", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "reported", "source_type": "Catalyst calendar", "source_url": "https://www.marketbeat.com/fda-calendar/upcoming/", "source_date": "2026-09-10", "verified_on": null, "outcome": null, "note": "No approved treatment for aPAP currently exists in the US. Needs confirming against the company's own filing.", "date_precision": "day", "date_display": null }, { "company": "Capricor Therapeutics", "ticker": "CAPR", "market": "Nasdaq", "drug": "Deramiocel", "indication": "Duchenne muscular dystrophy cardiomyopathy", "mechanism": "Allogeneic cardiosphere-derived cell therapy", "catalyst_date": "2026-11-22", "catalyst_type": "PDUFA date (extended)", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm", "source_date": "2026-08-24", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA \"extended the PDUFA target action date ... from August 22, 2026 to November 22, 2026\" after classifying a BLA amendment as a major submission. An extension is itself a signal worth showing.", "date_precision": "day", "date_display": null }, { "company": "BridgeBio Pharma", "ticker": "BBIO", "market": "Nasdaq", "drug": "BBP-418", "indication": "Limb-girdle muscular dystrophy type 2I/R9", "mechanism": "Glycosylation substrate therapy", "catalyst_date": "2026-11-27", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA is \"assigning a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026.\" Resolves the earlier ambiguity between two BridgeBio filings.", "date_precision": "day", "date_display": null }, { "company": "PolyPid Ltd.", "ticker": "PYPD", "market": "Nasdaq", "drug": "D-PLEX100", "indication": "Prevention of surgical site infection in abdominal colorectal surgery", "mechanism": "Locally delivered prolonged-release antibiotic", "catalyst_date": "2026-11-28", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "6-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1611842/000121390026082564/ea029964201ex99-1.htm", "source_date": "2026-07-29", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA \"did not identify any filing review issues and set a PDUFA target action date of November 28, 2026,\" a quarter earlier than the company had guided.", "date_precision": "day", "date_display": null }, { "company": "Cogent Biosciences", "ticker": "COGT", "market": "Nasdaq", "drug": "Bezuclastinib", "indication": "Gastrointestinal stromal tumour (GIST)", "mechanism": "Selective KIT inhibitor", "catalyst_date": "2026-11-30", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026.\" Catalyst calendars listed this date against systemic mastocytosis; the filing shows it is the GIST indication.", "date_precision": "day", "date_display": null }, { "company": "Zai Lab Ltd.", "ticker": "ZLAB", "market": "Nasdaq", "drug": "Povetacicept", "indication": "IgA nephropathy", "mechanism": "Dual APRIL/BAFF inhibitor, accelerated approval", "catalyst_date": "2026-11-30", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA accepted the BLA \"for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Kodiak Sciences", "ticker": "KOD", "market": "Nasdaq", "drug": "KSI-101", "indication": "Macular oedema secondary to inflammation (MESI)", "mechanism": "PEAK trial", "catalyst_date": "2026-12-01", "date_precision": "month", "date_display": "Dec 2026", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline data from Pivotal Analysis 1 are expected in December 2026.\"" }, { "company": "Vanda Pharmaceuticals", "ticker": "VNDA", "market": "Nasdaq", "drug": "Quimilza (imsidolimab)", "indication": "Generalised pustular psoriasis", "mechanism": "Anti-IL-36 receptor antibody", "catalyst_date": "2026-12-12", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the BLA \"is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Corcept Therapeutics", "ticker": "CORT", "market": "Nasdaq", "drug": "Relacorilant", "indication": "Cushing's syndrome", "mechanism": "Selective cortisol modulator", "catalyst_date": "2026-12-17", "catalyst_type": "FDA decision expected", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort072926ex991pressrelease.htm", "source_date": "2026-07-29", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"We expect a decision on our NDA by December 17, 2026.\" NDA was resubmitted in June 2026.", "date_precision": "day", "date_display": null }, { "company": "Praxis Precision Medicines", "ticker": "PRAX", "market": "Nasdaq", "drug": "Relutrigine", "indication": "SCN2A and SCN8A developmental epileptic encephalopathies", "mechanism": "Preferential sodium channel modulator", "catalyst_date": "2026-12-27", "catalyst_type": "PDUFA date (extended)", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K press release", "source_url": "https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA \"extended the review period for relutrigine's NDA and set a new PDUFA target action date of December 27, 2026.\" An extension is itself a signal worth noting.", "date_precision": "day", "date_display": null }, { "company": "Cogent Biosciences", "ticker": "COGT", "market": "Nasdaq", "drug": "Bezuclastinib", "indication": "Non-advanced systemic mastocytosis", "mechanism": "Selective KIT inhibitor", "catalyst_date": "2026-12-30", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Structure Therapeutics", "ticker": "GPCR", "market": "Nasdaq", "drug": "ACCG-2671", "indication": "Obesity", "mechanism": "Phase 1/2a MAD trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-11", "outcome": null, "note": "Amylin programme. Filing states \"topline data expected in the first half of 2027\" for the multiple-ascending-dose portion." }, { "company": "Maze Therapeutics", "ticker": "MAZE", "market": "Nasdaq", "drug": "MZE782", "indication": "Phenylketonuria (PKU)", "mechanism": "CIPheR trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline data from the trial is expected in 2027.\" Year-level guidance only." }, { "company": "Zura Bio", "ticker": "ZURA", "market": "Nasdaq", "drug": "Tibulizumab (ZB-106)", "indication": "Systemic sclerosis", "mechanism": "TibuSURE trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811xex991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline data are anticipated in the first half of 2027.\"" }, { "company": "Enanta Pharmaceuticals", "ticker": "ENTA", "market": "Nasdaq", "drug": "Zelicapavir", "indication": "RSV in high-risk adults", "mechanism": "RESOLVE trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 2/3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline Phase 2b data from RESOLVE is expected in 2027.\" Year-level guidance only." }, { "company": "LB Pharmaceuticals", "ticker": "LBRX", "market": "Nasdaq", "drug": "LB-102", "indication": "Schizophrenia", "mechanism": "NOVA-2 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/d303033dex991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states \"topline data is expected in the first half of 2027.\"" }, { "company": "Arcus Biosciences", "ticker": "RCUS", "market": "Nasdaq", "drug": "Quemliclustat", "indication": "First-line metastatic pancreatic ductal adenocarcinoma", "mechanism": "PRISM-1 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "CD73 inhibitor. Filing states: \"Results from this study are expected in the first half of 2027.\"" }, { "company": "aTyr Pharma", "ticker": "ATYR", "market": "Nasdaq", "drug": "Efzofitimod", "indication": "Systemic sclerosis-associated interstitial lung disease", "mechanism": "EFZO-CONNECT trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm", "source_date": "2026-08-07", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline results are expected in the first quarter of 2027.\"" }, { "company": "MacroGenics", "ticker": "MGNX", "market": "Nasdaq", "drug": "Lorigerlimab", "indication": "Clear cell gynaecologic cancer (PD-1 x CTLA-4)", "mechanism": "Phase 2 expansion trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/exhibit99-1earningspressre.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"anticipates reporting updated study results in the first half of 2027.\"" }, { "company": "Aptevo Therapeutics", "ticker": "APVO", "market": "Nasdaq", "drug": "Mipletamig", "indication": "Frontline acute myeloid leukaemia", "mechanism": "RAINIER regulatory interaction trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Regulatory milestone", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/apvo-ex99_1.htm", "source_date": "2026-09-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states a \"regulatory interaction is planned for 1H27 to determine next steps.\"" }, { "company": "PMV Pharmaceuticals", "ticker": "PMVP", "market": "Nasdaq", "drug": "Rezatapopt", "indication": "Platinum-resistant ovarian cancer, TP53 Y220C", "mechanism": "NDA submission trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/d441751dex991.htm", "source_date": "2026-08-31", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"The Company anticipates submitting an NDA in the first quarter of 2027\" under accelerated approval." }, { "company": "Climb Bio", "ticker": "CLYM", "market": "Nasdaq", "drug": "CLYM116 (budoprutug)", "indication": "IgA nephropathy / autoimmune (CD19 antibody)", "mechanism": "NAVIGATE-2 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/d97033dex992.htm", "source_date": "2026-09-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Initial data anticipated in 1H 2027; designed to confirm integrated Phase 1 PK/PD modeling and support advancing Q12W regimen into Phase 3.\"" }, { "company": "Ocugen", "ticker": "OCGN", "market": "Nasdaq", "drug": "OCU400", "indication": "Retinitis pigmentosa (modifier gene therapy)", "mechanism": "liMeliGhT trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-2.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Company slide guides \"Topline data: 1Q 2027.\"" }, { "company": "Jasper Therapeutics", "ticker": "JSPR", "market": "Nasdaq", "drug": "Briquilimab", "indication": "Chronic spontaneous urticaria / mast cell disease", "mechanism": "Pre-BLA meeting trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Regulatory milestone", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/ea030204901ex99-1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"expects to announce next steps in the first quarter of 2027\" following pre-BLA engagement." }, { "company": "Jade Biosciences", "ticker": "JBIO", "market": "Nasdaq", "drug": "JADE101", "indication": "IgA nephropathy (APRIL antibody)", "mechanism": "JUNIPER trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Interim data are expected in 2027.\" Year-level guidance only." }, { "company": "Jade Biosciences", "ticker": "JBIO", "market": "Nasdaq", "drug": "JADE201", "indication": "Rheumatoid arthritis", "mechanism": "Phase 1 trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"interim, biomarker-rich data expected in 2027.\"" }, { "company": "Roivant Sciences", "ticker": "ROIV", "market": "Nasdaq", "drug": "IMVT-1402", "indication": "Graves’ disease and myasthenia gravis", "mechanism": "Registrational trials trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG\" in calendar 2027." }, { "company": "Seaport Therapeutics", "ticker": "SPTX", "market": "Nasdaq", "drug": "GlyphAllo", "indication": "Major depressive disorder", "mechanism": "BUOY-1 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2B readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-ex99_1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Topline data from the BUOY-1 trial are expected in the first half of 2027.\"" }, { "company": "Alumis", "ticker": "ALMS", "market": "Nasdaq", "drug": "Envudeucitinib", "indication": "Plaque psoriasis", "mechanism": "Phase 2 long-term extension trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-2.htm", "source_date": "2026-09-01", "verified_on": "2026-09-12", "outcome": null, "note": "Company milestone slide guides \"1H27: Two-Year Safety Data.\"" }, { "company": "Alumis", "ticker": "ALMS", "market": "Nasdaq", "drug": "Envudeucitinib", "indication": "Plaque psoriasis", "mechanism": "NDA filing trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-2.htm", "source_date": "2026-09-01", "verified_on": "2026-09-12", "outcome": null, "note": "Company milestone slide guides \"2027: NDA Filing.\"" }, { "company": "Septerna", "ticker": "SEPN", "market": "Nasdaq", "drug": "SEP-479", "indication": "Hypoparathyroidism (oral PTH1R agonist)", "mechanism": "Phase 1 SAD/MAD trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/sepn-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.\"" }, { "company": "TuHURA Biosciences", "ticker": "HURA", "market": "Nasdaq", "drug": "IFx-2.0 + pembrolizumab", "indication": "Deep-seated Merkel cell carcinoma", "mechanism": "Investigator study trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Clinical readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/hura-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"preliminary results from IR study IFX-2.0 with Keytruda for deep seated MCC\" in 1H 2027." }, { "company": "TuHURA Biosciences", "ticker": "HURA", "market": "Nasdaq", "drug": "TBS-2025", "indication": "NPM1-mutated relapsed/refractory AML (VISTA antibody)", "mechanism": "Phase 1 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/hura-ex99_1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"preliminary safety and response data for VISTA in mutated NMP1 r/r AML\" in 1H 2027." }, { "company": "CervoMed", "ticker": "CRVO", "market": "Nasdaq", "drug": "Neflamapimod", "indication": "Non-fluent variant primary progressive aphasia", "mechanism": "Phase 2a nfvPPA topline trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 2A readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"Initial topline clinical data, as well as additional biomarker data\" in Q1 2027." }, { "company": "Definium Therapeutics", "ticker": "DFTX", "market": "Nasdaq", "drug": "DT120 ODT", "indication": "Major depressive disorder", "mechanism": "Ascend trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline data expected in 2027.\" Year-level guidance only." }, { "company": "Absci", "ticker": "ABSI", "market": "Nasdaq", "drug": "ABS-201", "indication": "Androgenetic (pattern) hair loss", "mechanism": "26-week proof-of-concept trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "Early 2027", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"our full 26-week readout in early 2027.\"" }, { "company": "Faeth Therapeutics", "ticker": "FTH", "market": "Nasdaq", "drug": "PIK-101 (PIKTOR)", "indication": "HR-positive breast cancer", "mechanism": "Phase 1b/2 trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 1B/2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/d168633dex991.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"We look forward to reporting initial safety and efficacy data from PIK-101 in 2027.\"" }, { "company": "Xencor", "ticker": "XNCR", "market": "Nasdaq", "drug": "XmAb412", "indication": "Inflammatory disease (TL1A x IL23p19)", "mechanism": "First-in-human trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Xencor \"initiated a first-in-human study of XmAb412 in the third quarter of 2026 and plans to present initial data from the study in 1H27.\"" }, { "company": "Erasca", "ticker": "ERAS", "market": "Nasdaq", "drug": "ERAS-0015", "indication": "RAS-mutant solid tumours (pan-RAS inhibitor)", "mechanism": "AURORAS-1 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/eras-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Phase 1 monotherapy expansion data expected in the first half of 2027.\"" }, { "company": "Erasca", "ticker": "ERAS", "market": "Nasdaq", "drug": "ERAS-0015 + panitumumab", "indication": "RAS-mutant colorectal cancer", "mechanism": "AURORAS combination trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/eras-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027.\"" }, { "company": "CytomX Therapeutics", "ticker": "CTMX", "market": "Nasdaq", "drug": "Varseta-M + bevacizumab", "indication": "Metastatic colorectal cancer", "mechanism": "Phase 1 combination trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Initial clinical data is anticipated in 1H 2027.\"" }, { "company": "CytomX Therapeutics", "ticker": "CTMX", "market": "Nasdaq", "drug": "CX-801 + pembrolizumab", "indication": "Advanced melanoma (masked interferon alpha-2b)", "mechanism": "Phase 1 combination trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Initial clinical data for CX-801 in combination with KEYTRUDA in advanced melanoma is expected in the first half of 2027.\"" }, { "company": "Whitehawk Therapeutics", "ticker": "WHWK", "market": "Nasdaq", "drug": "HWK-007", "indication": "EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer", "mechanism": "Phase 1 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"initial results expected in 1H 2027\" for the Phase 1 programme." }, { "company": "Whitehawk Therapeutics", "ticker": "WHWK", "market": "Nasdaq", "drug": "HWK-016", "indication": "Advanced ovarian and endometrial cancers", "mechanism": "Phase 1 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"initial results expected in 1H 2027\" for the Phase 1 programme." }, { "company": "Stoke Therapeutics", "ticker": "STOK", "market": "Nasdaq", "drug": "STK-002", "indication": "Autosomal dominant optic atrophy", "mechanism": "OSPREY trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-ex99_1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"initial data anticipated in H1 2027\" with a \"readout of safety and efficacy results anticipated in the first half of 2027.\"" }, { "company": "Stoke Therapeutics", "ticker": "STOK", "market": "Nasdaq", "drug": "Zorevunersen", "indication": "Dravet syndrome", "mechanism": "Rolling NDA submission trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-ex99_1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states a \"rolling U.S. NDA submission planned to initiate in Q1 2027\" after an H2 2026 pre-NDA meeting." }, { "company": "Fractyl Health", "ticker": "GUTS", "market": "Nasdaq", "drug": "Revita", "indication": "Post-GLP-1 weight maintenance — one-year data", "mechanism": "REMAIN-1 one-year trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Clinical readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1572616/000119312526342343/guts-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"Topline one-year data from the REMAIN-1 Pivotal Cohort\" in Q1 2027." }, { "company": "Sana Biotechnology", "ticker": "SANA", "market": "Nasdaq", "drug": "SG293", "indication": "Non-Hodgkin lymphoma (in vivo CAR-T)", "mechanism": "First-in-human trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1770121/000119312526384405/d170343dex991.htm", "source_date": "2026-09-08", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"SG293 in non-Hodgkin lymphoma — potential to share first-in-human data in 1H 2027.\"" }, { "company": "Aktis Oncology", "ticker": "AKTS", "market": "Nasdaq", "drug": "AKY-1189", "indication": "Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical)", "mechanism": "NECTINIUM-2 trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Expect preliminary data from the ongoing Phase 1b NECTINIUM-2 clinical trial in the first quarter of 2027.\"" }, { "company": "Aktis Oncology", "ticker": "AKTS", "market": "Nasdaq", "drug": "AKY-2519", "indication": "Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical)", "mechanism": "BActinium-1 trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Expect preliminary data from Phase 1b mCRPC clinical trial in 2027.\" Year-level guidance only." }, { "company": "Cartesian Therapeutics", "ticker": "RNAC", "market": "Nasdaq", "drug": "Descartes-08", "indication": "Myasthenia gravis (mRNA CAR-T)", "mechanism": "AURORA trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/exhibit991_earningsrelease.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the \"Phase 3 AURORA trial of Descartes-08 in myasthenia gravis continues to advance; data expected in 1Q27.\"" }, { "company": "Cartesian Therapeutics", "ticker": "RNAC", "market": "Nasdaq", "drug": "Descartes-08", "indication": "Myositis", "mechanism": "TRITON trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/exhibit991_earningsrelease.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27.\"" }, { "company": "Cartesian Therapeutics", "ticker": "RNAC", "market": "Nasdaq", "drug": "Descartes-08", "indication": "Juvenile dermatomyositis (paediatric)", "mechanism": "HELIOS trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/exhibit991_earningsrelease.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the \"Phase 1/2 HELIOS pediatric trial ... continues to progress with data expected in 1H27.\"" }, { "company": "Scribe Therapeutics", "ticker": "SCTX", "market": "Nasdaq", "drug": "STX-1150", "indication": "Elevated LDL-C and ASCVD risk (in vivo CRISPR)", "mechanism": "Phase 1 SAD trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1853921/000119312526380184/sctx-ex99_1.htm", "source_date": "2026-09-02", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Scribe \"anticipates reporting initial clinical data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose (SAD) portion of the STX-1150 Phase 1 trial in the first half of 2027.\"" }, { "company": "Tempest Therapeutics", "ticker": "TPST", "market": "Nasdaq", "drug": "TPST-4003", "indication": "Myasthenia gravis / multiple sclerosis (CD7 in vivo CAR-T)", "mechanism": "Investigator-initiated trial trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/tpst-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"initial clinical data expected in the first half of 2027,\" with first patient dosing in Q4 2026." }, { "company": "Kailera Therapeutics", "ticker": "KLRA", "market": "Nasdaq", "drug": "KAI-7535", "indication": "Obesity", "mechanism": "Phase 2 trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"The trial initiated in April 2026, with data expected in 2027.\" Year-level guidance only." }, { "company": "Kailera Therapeutics", "ticker": "KLRA", "market": "Nasdaq", "drug": "KAI-4729", "indication": "Obesity", "mechanism": "Phase 1 trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Kailera \"remains on track to begin a Phase 1 trial in 2026 with data anticipated in 2027.\"" }, { "company": "Rapport Therapeutics", "ticker": "RAPP", "market": "Nasdaq", "drug": "RAP-219 long-acting injectable", "indication": "Neurological disorders (LAI formulation)", "mechanism": "Phase 1 PK trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"initial Phase 1 pharmacokinetic data expected in 2027.\"" }, { "company": "Arvinas", "ticker": "ARVN", "market": "Nasdaq", "drug": "ARV-027", "indication": "Kennedy’s disease (polyQ-AR degrader)", "mechanism": "Phase 1 trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides sharing \"initial data evaluating androgen receptor (AR)-degradation in muscle.\"" }, { "company": "Celldex Therapeutics", "ticker": "CLDX", "market": "Nasdaq", "drug": "Barzolvolimab", "indication": "Chronic spontaneous urticaria", "mechanism": "BLA submission trial", "catalyst_date": "2027-01-01", "date_precision": "year", "date_display": "2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/exh_991.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"BLA submission planned for 2027.\"" }, { "company": "Kardigan", "ticker": "KARD", "market": "Nasdaq", "drug": "Danicamtiv", "indication": "Genetic dilated cardiomyopathy", "mechanism": "KINSHIP-DCM trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2B readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526343395/ck0002123613-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"The Company expects to share Phase 2b topline data in the first half of 2027.\"" }, { "company": "Kardigan", "ticker": "KARD", "market": "Nasdaq", "drug": "Ataciguat", "indication": "Calcific aortic valve stenosis (interim 24-week analysis)", "mechanism": "KATALYST-AV trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2B readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526343395/ck0002123613-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"expects to share Phase 2b topline data from the interim 24-week analysis in the first half of 2027.\"" }, { "company": "Kardigan", "ticker": "KARD", "market": "Nasdaq", "drug": "Tonlamarsen", "indication": "Acute severe hypertension", "mechanism": "KARDINAL-ASH trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 2 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526343395/ck0002123613-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"expects to share Phase 2 topline data in the first half of 2027.\"" }, { "company": "Palvella Therapeutics", "ticker": "PVLA", "market": "Nasdaq", "drug": "QTORIN rapamycin", "indication": "Microcystic lymphatic malformations", "mechanism": "FDA decision trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "FDA decision expected", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1583648/000119312526303307/pvla-ex99_1.htm", "source_date": "2026-07-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"Potential FDA approval and U.S. launch 1H 2027.\" No PDUFA date has been assigned yet — this is company expectation, not an FDA commitment." }, { "company": "EyePoint", "ticker": "EYPT", "market": "Nasdaq", "drug": "DURAVYU (vorolanib insert)", "indication": "Wet age-related macular degeneration", "mechanism": "NDA submission trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm", "source_date": "2026-09-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides submission of the \"comprehensive Phase 3 data package (LUGANO & LUCIA) to FDA\" in H1 2027." }, { "company": "Olema Pharmaceuticals", "ticker": "OLMA", "market": "Nasdaq", "drug": "Palazestrant (OP-1250)", "indication": "ER+/HER2- advanced breast cancer, 2nd/3rd line", "mechanism": "OPERA-01 trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company will \"Report top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027.\"" }, { "company": "Annovis Bio", "ticker": "ANVS", "market": "Nasdaq", "drug": "Buntanetap", "indication": "Alzheimer’s disease — 6-month symptomatic data", "mechanism": "Phase 3 Alzheimer’s trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_ex99-1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states a \"database lock for the 6-month analysis in Q1 2027, with the top-line symptomatic data readout anticipated in the same quarter.\"" }, { "company": "Inhibikase Therapeutics", "ticker": "IKT", "market": "Nasdaq", "drug": "IKT-001 (imatinib prodrug)", "indication": "Pulmonary arterial hypertension — interim safety (n=50)", "mechanism": "IMPROVE-PAH Part A interim trial", "catalyst_date": "2027-01-01", "date_precision": "half", "date_display": "H1 2027", "catalyst_type": "Phase 3 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/d152999dex991.htm", "source_date": "2026-09-08", "verified_on": "2026-09-12", "outcome": null, "note": "Company deck guides an \"Interim safety readout for Part A of Phase 3 IMPROVE-PAH Study (n=50)\" in 1H 2027." }, { "company": "Atea Pharmaceuticals", "ticker": "AVIR", "market": "Nasdaq", "drug": "Bemnifosbuvir + ruzasvir", "indication": "Chronic hepatitis C", "mechanism": "C-FORWARD trial", "catalyst_date": "2027-01-01", "date_precision": "quarter", "date_display": "Q1 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663dex991.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline results are expected in early Q1 2027 and will provide additional efficacy data across a broader range of HCV genotypes.\"" }, { "company": "ImmunityBio", "ticker": "IBRX", "market": "Nasdaq", "drug": "ANKTIVA (nogapendekin alfa) plus BCG", "indication": "BCG-unresponsive NMIBC with papillary disease", "mechanism": "IL-15 receptor agonist, sBLA", "catalyst_date": "2027-01-06", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-202684x8kexhibit991.htm", "source_date": "2026-08-04", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA accepted the sBLA and \"assigned a PDUFA target action date of January 6, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Dyne Therapeutics", "ticker": "DYN", "market": "Nasdaq", "drug": "z-rostudirsen (DYNE-251)", "indication": "Duchenne muscular dystrophy, exon 51 skipping", "mechanism": "FORCE platform antisense conjugate", "catalyst_date": "2027-01-21", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm", "source_date": "2026-07-29", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"PDUFA target action date set for January 21, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Praxis Precision Medicines", "ticker": "PRAX", "market": "Nasdaq", "drug": "Ulixacaltamide", "indication": "Essential tremor", "mechanism": "T-type calcium channel blocker", "catalyst_date": "2027-01-29", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K press release", "source_url": "https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"NDA review is progressing as expected, with a PDUFA date of January 29, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Belite Bio", "ticker": "BLTE", "market": "Nasdaq", "drug": "Tinlarebant", "indication": "Stargardt disease type 1", "mechanism": "Oral RBP4 antagonist", "catalyst_date": "2027-02-12", "catalyst_type": "PDUFA date", "options": false, "status": "upcoming", "verification": "verified", "source_type": "6-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1889109/000110465926105608/tm2624806d1_ex99-1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states a \"Prescription Drug User Fee Act target action date of February 12, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Arcutis Biotherapeutics", "ticker": "ARQT", "market": "Nasdaq", "drug": "ZORYVE (roflumilast) cream 0.05%", "indication": "Atopic dermatitis in infants aged 3–24 months", "mechanism": "Topical PDE4 inhibitor, sNDA", "catalyst_date": "2027-02-23", "catalyst_type": "PDUFA date", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm", "source_date": "2026-08-05", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA accepted the sNDA \"with a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Cullinan Therapeutics", "ticker": "CGEM", "market": "Nasdaq", "drug": "Zipalertinib", "indication": "EGFR exon 20 insertion NSCLC, second line", "mechanism": "EGFR ex20ins-selective inhibitor", "catalyst_date": "2027-02-27", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"The Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Apnimed", "ticker": "APMD", "market": "Nasdaq", "drug": "AD109 (Oxnimbi)", "indication": "Obstructive sleep apnoea in adults", "mechanism": "Oral neuromuscular modulator", "catalyst_date": "2027-02-28", "catalyst_type": "PDUFA date", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Intellia Therapeutics", "ticker": "NTLA", "market": "Nasdaq", "drug": "Lonvoguran ziclumeran (lonvo-z)", "indication": "Hereditary angioedema (HAE)", "mechanism": "In vivo CRISPR gene editing", "catalyst_date": "2027-03-10", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1652130/000119312526385194/ntla-ex99_1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-11", "outcome": null, "note": "Filing headline: \"FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027.\" Would be among the first in vivo CRISPR therapies to reach an FDA decision.", "date_precision": "day", "date_display": null }, { "company": "Harmony Biosciences Holdings", "ticker": "HRMY", "market": "Nasdaq", "drug": "Pitolisant GR", "indication": "Narcolepsy", "mechanism": "Histamine H3 receptor antagonist, gastro-resistant formulation", "catalyst_date": "2027-04-01", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm", "source_date": "2026-08-04", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"NDA accepted by FDA in July; target PDUFA date of April 1, 2027.\" The same filing flags further pitolisant PDUFA dates anticipated in 2028.", "date_precision": "day", "date_display": null }, { "company": "4D Molecular Therapeutics", "ticker": "FDMT", "market": "Nasdaq", "drug": "4D-150", "indication": "Wet age-related macular degeneration", "mechanism": "4FRONT-1 trial", "catalyst_date": "2027-04-01", "date_precision": "quarter", "date_display": "Q2 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-11", "outcome": null, "note": "Intravitreal gene therapy. Filing states \"4FRONT-1 Phase 3 topline data expected in Q2 2027.\"" }, { "company": "Kodiak Sciences", "ticker": "KOD", "market": "Nasdaq", "drug": "KSI-101", "indication": "Macular oedema secondary to inflammation (MESI)", "mechanism": "PEAK and PINNACLE trial", "catalyst_date": "2027-04-01", "date_precision": "quarter", "date_display": "Q2 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline data anticipated in the second quarter of 2027.\"" }, { "company": "Ocugen", "ticker": "OCGN", "market": "Nasdaq", "drug": "OCU410ST", "indication": "Stargardt disease", "mechanism": "Topline trial", "catalyst_date": "2027-04-01", "date_precision": "quarter", "date_display": "Q2 2027", "catalyst_type": "Phase 2/3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-2.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Company slide guides \"Topline data: 2Q 2027.\"" }, { "company": "Ocugen", "ticker": "OCGN", "market": "Nasdaq", "drug": "OCU400", "indication": "Retinitis pigmentosa", "mechanism": "BLA submission trial", "catalyst_date": "2027-04-01", "date_precision": "quarter", "date_display": "Q2 2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-2.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Company slide guides \"BLA target: 2Q 2027.\"" }, { "company": "Context Therapeutics", "ticker": "CNTX", "market": "Nasdaq", "drug": "CTIM-76", "indication": "Platinum-resistant ovarian cancer (Claudin 6 x CD3)", "mechanism": "Phase 1a Q3W dosing trial", "catalyst_date": "2027-04-01", "date_precision": "quarter", "date_display": "Q2 2027", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1842952/000162828026053378/a2026aug-contextxcorpdec.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Company deck guides \"Q2 2027: Phase 1a initial Q3W dosing data.\"" }, { "company": "Atea Pharmaceuticals", "ticker": "AVIR", "market": "Nasdaq", "drug": "Bemnifosbuvir + ruzasvir", "indication": "Chronic hepatitis C", "mechanism": "NDA submission trial", "catalyst_date": "2027-04-01", "date_precision": "quarter", "date_display": "Q2 2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663dex991.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states Atea \"anticipates submitting a new drug application (NDA) to the FDA in the second quarter of 2027.\"" }, { "company": "Pharvaris N.V.", "ticker": "PHVS", "market": "Nasdaq", "drug": "Deucrictibant IR", "indication": "Hereditary angioedema, on-demand treatment", "mechanism": "Oral bradykinin B2 receptor antagonist", "catalyst_date": "2027-04-23", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "6-K exhibit 99.2", "source_url": "https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_2.htm", "source_date": "2026-08-12", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the NDA \"is currently under review with the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Immunome", "ticker": "IMNM", "market": "Nasdaq", "drug": "Varegacestat", "indication": "Desmoid tumours", "mechanism": "Oral gamma secretase inhibitor", "catalyst_date": "2027-04-28", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the FDA accepted the NDA \"for varegacestat for the treatment of adults with desmoid tumors and assigned a PDUFA target action date of April 28, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Axsome Therapeutics", "ticker": "AXSM", "market": "Nasdaq", "drug": "AXS-12 (reboxetine)", "indication": "Cataplexy in narcolepsy", "mechanism": "Norepinephrine reuptake inhibitor", "catalyst_date": "2027-05-01", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the NDA \"was accepted by the FDA and assigned a PDUFA target action date of May 1, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "Verastem Oncology", "ticker": "VSTM", "market": "Nasdaq", "drug": "Avutometinib + defactinib", "indication": "Recurrent low-grade serous ovarian cancer", "mechanism": "RAMP 301 trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_ex99-1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states the company will \"report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027.\"" }, { "company": "Allogene Therapeutics", "ticker": "ALLO", "market": "Nasdaq", "drug": "Cemacabtagene ansegedleucel", "indication": "First-line large B-cell lymphoma consolidation", "mechanism": "ALPHA3 trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/allo-20260630xexx991q226.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"The next program update tied to the interim event-free survival (EFS) analysis is expected in mid-2027.\"" }, { "company": "Ocugen", "ticker": "OCGN", "market": "Nasdaq", "drug": "OCU410ST", "indication": "Stargardt disease", "mechanism": "BLA submission trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-2.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Company slide guides \"BLA target: Mid-2027.\"" }, { "company": "Cartesian Therapeutics", "ticker": "RNAC", "market": "Nasdaq", "drug": "Descartes-08", "indication": "Myasthenia gravis", "mechanism": "BLA filing trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/exhibit991_earningsrelease.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states a \"biologics license application (BLA) filing planned for mid-2027.\"" }, { "company": "C4 Therapeutics", "ticker": "CCCC", "market": "Nasdaq", "drug": "Cemsidomide + elranatamab", "indication": "Multiple myeloma", "mechanism": "Phase 1b all cohorts trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Phase 1B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811xexx991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"data from all cohorts expected in mid-2027.\"" }, { "company": "Kailera Therapeutics", "ticker": "KLRA", "market": "Nasdaq", "drug": "Ribupatide (KAI-9531)", "indication": "Obesity (48-week high-dose trial)", "mechanism": "Phase 2b high dose trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Phase 2B readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the trial evaluates once-weekly doses over 48 weeks and \"Data are anticipated in mid-2027.\"" }, { "company": "Arvinas", "ticker": "ARVN", "market": "Nasdaq", "drug": "ARV-393", "indication": "B- and T-cell lymphomas (BCL6 degrader)", "mechanism": "Phase 1 B- and T-cell lymphoma trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"additional monotherapy data from the ongoing Phase 1 dose escalation trial in B- and T-cell lymphomas.\"" }, { "company": "Arvinas", "ticker": "ARVN", "market": "Nasdaq", "drug": "ARV-393 + glofitamab", "indication": "Diffuse large B-cell lymphoma", "mechanism": "Phase 1 combination trial", "catalyst_date": "2027-05-01", "date_precision": "half", "date_display": "Mid 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm", "source_date": "2026-08-04", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"data from the combination cohort with glofitamab in patients with DLBCL in the ongoing Phase 1 clinical trial.\"" }, { "company": "BridgeBio Pharma", "ticker": "BBIO", "market": "Nasdaq", "drug": "Encaleret", "indication": "Autosomal dominant hypocalcaemia type 1 (ADH1)", "mechanism": "Calcium-sensing receptor antagonist", "catalyst_date": "2027-05-08", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm", "source_date": "2026-08-10", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"with a PDUFA target action date of May 8, 2027.\" The same filing notes an NDA for oral infigratinib in achondroplasia is submitted with no date set yet.", "date_precision": "day", "date_display": null }, { "company": "Zenas BioPharma", "ticker": "ZBIO", "market": "Nasdaq", "drug": "Obexelimab", "indication": "Immunoglobulin G4-related disease (IgG4-RD)", "mechanism": "Bifunctional CD19 and FcγRIIb antibody", "catalyst_date": "2027-05-27", "catalyst_type": "PDUFA date", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"The BLA has a Prescription Drug User Fee Act (PDUFA) target action date of May 27, 2027.\"", "date_precision": "day", "date_display": null }, { "company": "4D Molecular Therapeutics", "ticker": "FDMT", "market": "Nasdaq", "drug": "4D-150", "indication": "Wet age-related macular degeneration", "mechanism": "4FRONT-2 trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm", "source_date": "2026-08-13", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states \"topline data expected in H2 2027\" for the second Phase 3." }, { "company": "Aura Biosciences", "ticker": "AURA", "market": "Nasdaq", "drug": "Belzupacap sarotalocan (bel-sar)", "indication": "Early-stage choroidal melanoma", "mechanism": "CoMpass trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-ex99_1.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Topline data from the 15-month primary endpoint remain on track for the second half of 2027.\"" }, { "company": "Jade Biosciences", "ticker": "JBIO", "market": "Nasdaq", "drug": "JADE301", "indication": "Dermatomyositis", "mechanism": "Phase 1 healthy volunteers trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 1 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm", "source_date": "2026-08-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"interim data anticipated in the second half of 2027.\"" }, { "company": "Context Therapeutics", "ticker": "CNTX", "market": "Nasdaq", "drug": "CT-202", "indication": "Urothelial, colorectal and triple-negative breast cancer (Nectin-4 x CD3)", "mechanism": "Phase 1a trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1842952/000162828026053378/a2026aug-contextxcorpdec.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Company deck guides \"2H 2027: Phase 1a initial data.\"" }, { "company": "Annexon", "ticker": "ANNX", "market": "Nasdaq", "drug": "Vonaprument", "indication": "Geographic atrophy (Month 24)", "mechanism": "ARCHER II final trial", "catalyst_date": "2027-07-01", "date_precision": "quarter", "date_display": "Q3 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1528115/000119312526345672/d119960dex991.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Final trial completion, including the Month 24 primary endpoint expected in the third quarter of 2027.\"" }, { "company": "Lexeo Therapeutics", "ticker": "LXEO", "market": "Nasdaq", "drug": "LX2006", "indication": "Friedreich ataxia cardiomyopathy (gene therapy)", "mechanism": "Registrational trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 1/2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline data readout expected in second half of 2027.\"" }, { "company": "Absci", "ticker": "ABSI", "market": "Nasdaq", "drug": "ABS-201", "indication": "Endometriosis", "mechanism": "Phase 2 proof-of-concept trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"potential proof-of-concept data in the second half of 2027.\"" }, { "company": "Xencor", "ticker": "XNCR", "market": "Nasdaq", "drug": "XmAb942", "indication": "Ulcerative colitis (12-week induction)", "mechanism": "XENITH-UC primary endpoint trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm", "source_date": "2026-08-05", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides \"reaching the primary endpoint of the 12-week induction period in 2H27.\"" }, { "company": "Xilio Therapeutics", "ticker": "XLO", "market": "Nasdaq", "drug": "XTX501", "indication": "Metastatic NSCLC (masked PD-1/IL-2 bispecific)", "mechanism": "Phase 1 trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 1 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Xilio plans to report initial Phase 1 data in patients with metastatic NSCLC in the second half of 2027.\"" }, { "company": "Stoke Therapeutics", "ticker": "STOK", "market": "Nasdaq", "drug": "Zorevunersen", "indication": "Dravet syndrome", "mechanism": "EMPEROR trial", "catalyst_date": "2027-07-01", "date_precision": "quarter", "date_display": "Q3 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-ex99_1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the Phase 3 EMPEROR \"data readout anticipated in Q3 2027.\"" }, { "company": "C4 Therapeutics", "ticker": "CCCC", "market": "Nasdaq", "drug": "Cemsidomide + dexamethasone", "indication": "Relapsed/refractory multiple myeloma", "mechanism": "MOMENTUM trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811xexx991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"The initial investigator-assessed overall response rate (ORR) data are expected in the second half of 2027.\"" }, { "company": "Palvella Therapeutics", "ticker": "PVLA", "market": "Nasdaq", "drug": "QTORIN rapamycin", "indication": "Clinically significant angiokeratomas", "mechanism": "Phase 2 trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1583648/000119312526303307/pvla-ex99_1.htm", "source_date": "2026-07-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Phase 2 data expected 2H 2027.\"" }, { "company": "Theriva Biologics", "ticker": "TOVX", "market": "Nasdaq", "drug": "VCN-01", "indication": "Metastatic pancreatic ductal adenocarcinoma (oncolytic adenovirus)", "mechanism": "VIRAGE2 trial", "catalyst_date": "2027-07-01", "date_precision": "quarter", "date_display": "Q3 2027", "catalyst_type": "Phase 2A readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_ex99-1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027,\" with enrolment completing in H2 2026." }, { "company": "Altimmune", "ticker": "ALT", "market": "Nasdaq", "drug": "Pemvidutide", "indication": "Alcohol-associated liver disease", "mechanism": "RESTORE trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/alt-20260812xex99d1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"The Company expects to report topline data in the second half of 2027.\"" }, { "company": "Trevi Therapeutics", "ticker": "TRVI", "market": "Nasdaq", "drug": "Haduvio (nalbuphine ER)", "indication": "Chronic cough in idiopathic pulmonary fibrosis", "mechanism": "OCEAN-2 trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"topline results expected in the second half of 2027.\"" }, { "company": "Trevi Therapeutics", "ticker": "TRVI", "market": "Nasdaq", "drug": "Haduvio (nalbuphine ER)", "indication": "Refractory chronic cough", "mechanism": "LAKE trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 2B readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states the company \"expects to report topline results from the trial in the second half of 2027,\" with a sample-size re-estimation in Q4 2026." }, { "company": "Minerva Neurosciences", "ticker": "NERV", "market": "Nasdaq", "drug": "Roluperidone", "indication": "Negative symptoms of schizophrenia", "mechanism": "Phase 3 C19 Part A trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348dex991.htm", "source_date": "2026-08-07", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline data from Phase A of the trial is expected in the second half of 2027.\"" }, { "company": "MapLight Therapeutics", "ticker": "MPLT", "market": "Nasdaq", "drug": "ML-007C-MA", "indication": "Alzheimer’s disease psychosis (hallucinations and delusions)", "mechanism": "VISTA trial", "catalyst_date": "2027-07-01", "date_precision": "half", "date_display": "H2 2027", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086dex992.htm", "source_date": "2026-07-27", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"topline results expected in the second half of 2027.\"" }, { "company": "EyePoint", "ticker": "EYPT", "market": "Nasdaq", "drug": "DURAVYU (vorolanib insert)", "indication": "Diabetic macular oedema — both pivotal trials", "mechanism": "COMO and CAPRI trial", "catalyst_date": "2027-10-01", "date_precision": "quarter", "date_display": "Q4 2027", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm", "source_date": "2026-09-10", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides reporting \"topline data simultaneously for both pivotal DME trials, COMO and CAPRI\" in Q4 2027." }, { "company": "X4 Pharmaceuticals", "ticker": "XFOR", "market": "Nasdaq", "drug": "Mavorixafor", "indication": "Chronic neutropenia", "mechanism": "4WARD trial", "catalyst_date": "2028-01-01", "date_precision": "half", "date_display": "H1 2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1501697/000150169726000076/x4pharmaceuticalscorpora.htm", "source_date": "2026-09-09", "verified_on": "2026-09-11", "outcome": null, "note": "CXCR4 antagonist. Filing states \"Topline data expected in H1 2028; approval anticipated late 2028/early 2029.\"" }, { "company": "LB Pharmaceuticals", "ticker": "LBRX", "market": "Nasdaq", "drug": "LB-102", "indication": "Bipolar depression", "mechanism": "ILLUMINATE-1 trial", "catalyst_date": "2028-01-01", "date_precision": "quarter", "date_display": "Q1 2028", "catalyst_type": "Phase 2 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/d303033dex991.htm", "source_date": "2026-08-11", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states \"topline data expected in the first quarter of 2028.\"" }, { "company": "Ocular Therapeutix", "ticker": "OCUL", "market": "Nasdaq", "drug": "AXPAXLI (OTX-TKI)", "indication": "Wet age-related macular degeneration", "mechanism": "SOL-R topline trial", "catalyst_date": "2028-01-01", "date_precision": "quarter", "date_display": "Q1 2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states: \"Following these changes, topline SOL-R results are now expected in the first quarter of 2028.\" Timing was revised — worth watching for further moves." }, { "company": "Roivant Sciences", "ticker": "ROIV", "market": "Nasdaq", "drug": "Brepocitinib", "indication": "Cutaneous sarcoidosis", "mechanism": "Phase 3 trial", "catalyst_date": "2028-01-01", "date_precision": "year", "date_display": "2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"topline data expected in calendar year 2028.\"" }, { "company": "Roivant Sciences", "ticker": "ROIV", "market": "Nasdaq", "drug": "IMVT-1402", "indication": "CIDP and Sjögren’s disease", "mechanism": "Registrational trials trial", "catalyst_date": "2028-01-01", "date_precision": "year", "date_display": "2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"topline data are expected across potentially registrational trials of IMVT-1402 in CIDP and SjD\" in calendar 2028." }, { "company": "Seaport Therapeutics", "ticker": "SPTX", "market": "Nasdaq", "drug": "GlyphAgo", "indication": "Generalised anxiety disorder with sleep disturbance", "mechanism": "Proof-of-pharmacology trial", "catalyst_date": "2028-01-01", "date_precision": "half", "date_display": "Early 2028", "catalyst_type": "Phase 2A readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-ex99_1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Topline data from this trial are expected in early 2028.\"" }, { "company": "Lexeo Therapeutics", "ticker": "LXEO", "market": "Nasdaq", "drug": "LX2006", "indication": "Friedreich ataxia cardiomyopathy", "mechanism": "BLA submission trial", "catalyst_date": "2028-01-01", "date_precision": "half", "date_display": "H1 2028", "catalyst_type": "Regulatory submission", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides a \"Potential BLA submission under accelerated approval pathway in first half of 2028.\"" }, { "company": "Kailera Therapeutics", "ticker": "KLRA", "market": "Nasdaq", "drug": "Ribupatide (KAI-9531)", "indication": "Obesity (global Phase 3)", "mechanism": "KaiNETIC trial", "catalyst_date": "2028-01-01", "date_precision": "year", "date_display": "2028", "catalyst_type": "Phase 3 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm", "source_date": "2026-08-12", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Data are anticipated in 2028.\" Year-level guidance only." }, { "company": "Annovis Bio", "ticker": "ANVS", "market": "Nasdaq", "drug": "Buntanetap", "indication": "Alzheimer’s disease — disease-modifying data", "mechanism": "Phase 3 disease-modifying trial", "catalyst_date": "2028-01-01", "date_precision": "quarter", "date_display": "Q1 2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_ex99-1.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "Filing guides disease-modifying data \"expected a year later\" than the Q1 2027 symptomatic readout." }, { "company": "Trevi Therapeutics", "ticker": "TRVI", "market": "Nasdaq", "drug": "Haduvio (nalbuphine ER)", "indication": "Chronic cough in IPF — 52-week fixed dosing", "mechanism": "OCEAN-1 trial", "catalyst_date": "2028-01-01", "date_precision": "half", "date_display": "H1 2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-ex99_1.htm", "source_date": "2026-08-06", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline data from the 52-week fixed dosing OCEAN-1 trial is expected in the first half of 2028.\"" }, { "company": "Inhibikase Therapeutics", "ticker": "IKT", "market": "Nasdaq", "drug": "IKT-001 (imatinib prodrug)", "indication": "Pulmonary arterial hypertension — PVR reduction (n=120)", "mechanism": "IMPROVE-PAH Part A efficacy trial", "catalyst_date": "2028-05-01", "date_precision": "half", "date_display": "Mid 2028", "catalyst_type": "Phase 3 readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/d152999dex991.htm", "source_date": "2026-09-08", "verified_on": "2026-09-12", "outcome": null, "note": "Company deck guides \"Unblinded Data (PVR reduction) readout for Part A\" in mid-2028." }, { "company": "Structure Therapeutics", "ticker": "GPCR", "market": "Nasdaq", "drug": "Aleniglipron", "indication": "Obesity and overweight", "mechanism": "ACCOMPLISH-1 and -2 trial", "catalyst_date": "2028-07-01", "date_precision": "half", "date_display": "H2 2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-1.htm", "source_date": "2026-09-08", "verified_on": "2026-09-11", "outcome": null, "note": "Filing states \"topline data expected in 2H 2028\" for the Phase 3 ACCOMPLISH programme." }, { "company": "Skye Bioscience", "ticker": "SKYE", "market": "Nasdaq", "drug": "RXC008", "indication": "Fibrostenotic Crohn’s disease (GI-restricted pan-ROCK inhibitor)", "mechanism": "Phase 2 trial", "catalyst_date": "2028-07-01", "date_precision": "half", "date_display": "H2 2028", "catalyst_type": "Phase 2 readout", "options": false, "status": "upcoming", "verification": "needs_check", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/a260814_prxjointxskyexredx.htm", "source_date": "2026-08-14", "verified_on": "2026-09-12", "outcome": null, "note": "From a joint Skye/Redx release — confirm which listed entity carries the programme after the transaction before treating the ticker as settled. Filing guides \"topline data from the RXC008 Phase 2 clinical study, expected in H2 2028.\"" }, { "company": "Minerva Neurosciences", "ticker": "NERV", "market": "Nasdaq", "drug": "Roluperidone", "indication": "Negative symptoms of schizophrenia", "mechanism": "Phase 3 C19 Part B trial", "catalyst_date": "2028-07-01", "date_precision": "half", "date_display": "H2 2028", "catalyst_type": "Phase 3 readout", "options": true, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348dex991.htm", "source_date": "2026-08-07", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states \"Topline data from Phase B of the trial is expected in the second half of 2028.\"" }, { "company": "Seaport Therapeutics", "ticker": "SPTX", "market": "Nasdaq", "drug": "GlyphAgo", "indication": "Generalised anxiety disorder", "mechanism": "Phase 2b trial", "catalyst_date": "2028-10-01", "date_precision": "half", "date_display": "Late 2028", "catalyst_type": "Phase 2B readout", "options": false, "status": "upcoming", "verification": "verified", "source_type": "8-K exhibit 99.1", "source_url": "https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-ex99_1.htm", "source_date": "2026-08-03", "verified_on": "2026-09-12", "outcome": null, "note": "Filing states: \"Topline data from this trial are expected by year-end 2028.\"" }, { "company": "Spero Therapeutics", "ticker": "SPRO", "market": "Nasdaq", "drug": "Utebzi (tebipenem pivoxil)", "indication": "Complicated urinary tract infections including pyelonephritis", "mechanism": "Oral carbapenem", "catalyst_date": "2026-06-18", "catalyst_type": "PDUFA date", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K", "source_url": "https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395d8k.htm", "source_date": "2026-06-22", "verified_on": "2026-09-11", "outcome": "Approved 17 June 2026, one day ahead of the PDUFA date", "note": "Filing states approval \"was received in advance of FDA-assigned Prescription Drug User Fee Act (PDUFA) date of June 18, 2026.\"", "date_precision": "day", "date_display": null }, { "company": "Vera Therapeutics", "ticker": "VERA", "market": "Nasdaq", "drug": "Atacicept", "indication": "IgA nephropathy", "mechanism": "APRIL/BLyS inhibitor, accelerated approval", "catalyst_date": "2026-07-07", "catalyst_type": "PDUFA date", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K", "source_url": "https://www.sec.gov/Archives/edgar/data/1831828/000119312526297211/vera-20260707.htm", "source_date": "2026-07-07", "verified_on": "2026-09-14", "outcome": "Approved 7 July 2026, on the PDUFA date — FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression.", "note": "FDA granted TRUTAKNA (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression, per the 8-K filed the same day as the PDUFA date.", "date_precision": "day", "date_display": null }, { "company": "Outlook Therapeutics", "ticker": "OTLK", "market": "Nasdaq", "drug": "ONS-5010 / LYTENAVA (bevacizumab-vikg)", "indication": "Wet age-related macular degeneration", "mechanism": "Ophthalmic bevacizumab, Class 1 resubmission", "catalyst_date": "2026-07-29", "catalyst_type": "PDUFA date", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K", "source_url": "https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_8k.htm", "source_date": "2026-07-24", "verified_on": "2026-09-14", "outcome": "Approved 24 July 2026, five days ahead of the PDUFA date — FDA approved LYTENAVA (ONS-5010/bevacizumab-vikg) for wet AMD, the company’s first FDA-approved product after three earlier rejections.", "note": "Filing states the FDA \"approved the Company’s biologics license application for ONS-5010/LYTENAVA (bevacizumab-vikg)... for the treatment of neovascular (wet) age-related macular degeneration,\" calling it the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD.", "date_precision": "day", "date_display": null }, { "company": "Jazz Pharmaceuticals", "ticker": "JAZZ", "market": "Nasdaq", "drug": "Zanidatamab (Ziihera)", "indication": "HER2-positive first-line gastroesophageal adenocarcinoma", "mechanism": "Bispecific HER2-directed antibody", "catalyst_date": "2026-08-25", "catalyst_type": "PDUFA date", "options": true, "status": "decided", "verification": "verified", "source_type": "8-K", "source_url": "https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/jazz-20260825.htm", "source_date": "2026-08-25", "verified_on": "2026-09-14", "outcome": "Approved 25 August 2026, on the PDUFA date — FDA approved two Ziihera (zanidatamab-hrii) regimens (with and without Tevimbra/tislelizumab, plus chemotherapy) for first-line HER2-positive gastroesophageal adenocarcinoma.", "note": "Filing states the FDA \"approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA).\"", "date_precision": "day", "date_display": null } ]